Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
复制标题
DOI：
10.1183/09031936.00104612
复制
发表时间：
2013-12-01
影响因子：
24.3
通讯作者：
Behr, Juergen
中科院分区：
文献类型：
--
作者：
Raghu, Ganesh;Million-Rousseau, Rachel;Behr, Juergen
特发性肺纤维化是一种进行性、致命性疾病。这项前瞻性、随机、双盲、多中心、平行组、安慰剂对照的II期试验(NCT00903331)研究了内皮素受体拮抗剂马西坦治疗特发性肺纤维化的有效性和安全性。
Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis.Eligible subjects were adults with idiopathic pulmonary fibrosis of